30.96

0.16% 0.05

After Hours: 31.34 0.38 +1.23%

Ideaya Biosciences Inc (IDYA)

Overview News Price History Option Chain Financials Discussions Forecast

Ideaya Biosciences Inc stock is traded at $30.96, with a volume of 1.70M. It is up +0.16% in the last 24 hours and down -6.72% over the past month. IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Previous Close:

$30.91

Open:

$31.96

24h Volume:

1.70M

Relative Volume:

1.85

Market Cap:

$2.72B

Revenue:

$218.71M

Net Income/Loss:

$-113.70M

P/E Ratio:

-23.75

EPS:

-1.3034

Net Cash Flow:

$-73.47M

1W Performance:

-4.68%

1M Performance:

-6.72%

6M Performance:

+15.35%

1Y Performance:

+113.52%

1-Day Range:

$30.22

$32.30

1-Week Range:

$30.22

$33.65

52-Week Range:

$13.45

$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name

Ideaya Biosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (624)

Phone

650-443-6209

Address

5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

145

Twitter

Next Earnings Date

2026-02-13

Latest SEC Filings

IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDYA Ideaya Biosciences Inc	30.96	2.71B	218.71M	-113.70M	-73.47M	-1.3034
VRTX Vertex Pharmaceuticals Inc	443.92	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	775.53	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	785.07	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	327.25	42.63B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.19	33.72B	5.36B	287.73M	924.18M	2.5229

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Resumed	UBS	Buy
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Guggenheim	Buy
Sep-04-25	Initiated	Barclays	Overweight
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-26-25	Initiated	Wells Fargo	Overweight
Nov-18-24	Initiated	Stephens	Overweight
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform
Oct-24-24	Initiated	UBS	Buy
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform
Mar-08-24	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	SVB Securities	Outperform
May-24-23	Initiated	Goldman	Buy
Apr-24-23	Upgrade	Stifel	Hold → Buy
Mar-23-23	Initiated	Berenberg	Buy
Feb-28-23	Initiated	RBC Capital Mkts	Outperform
Dec-28-22	Initiated	CapitalOne	Overweight
Oct-27-22	Initiated	Citigroup	Buy
Aug-15-22	Downgrade	Stifel	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-10-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-11-21	Initiated	Guggenheim	Buy
Oct-07-20	Initiated	Wedbush	Outperform
Sep-01-20	Initiated	Northland Capital	Outperform
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-06-20	Initiated	H.C. Wainwright	Buy
Mar-13-20	Initiated	ROTH Capital	Buy
Oct-17-19	Initiated	Oppenheimer	Outperform
Sep-10-19	Initiated	Robert W. Baird	Outperform
Jun-17-19	Initiated	Citigroup	Buy
Jun-17-19	Initiated	JP Morgan	Neutral
Jun-17-19	Initiated	Jefferies	Buy

View All

Ideaya Biosciences Inc Stock (IDYA) Latest News

05:04 AM

Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha

05:04 AM

Apr 07, 2026

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail

Apr 07, 2026

Apr 06, 2026

IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC

Apr 06, 2026

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat

Apr 06, 2026

Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada

Apr 06, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView

Apr 06, 2026

Apr 05, 2026

IDEAYA Biosciences announced that the first patient has been dosed in a Phase I clinical trial of Ide574, its potential first-in-class dual inhibitor targeting Kat6/7. - Bitget

Apr 05, 2026

Apr 04, 2026

IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI

Apr 04, 2026

Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance

Apr 04, 2026

Apr 03, 2026

A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance

Apr 03, 2026